Abiraterone and Increased Survival in Metastatic Prostate Cancer

Abstract

This chapter summarizes the findings of a landmark trial conducted in men with castrate-resistant prostate cancer who had received prior chemotherapy comparing abiraterone to placebo. It demonstrated improved progression-free and overall survival. It was relatively well tolerated, with most adverse effects related to mineralocorticoid excess.